Skip to content

Author

J. Meyerhardt

We have 5 of 82 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Identification of prediagnostic proteomic biomarkers for colon and rectal cancer in 3 prospective cohorts.

It is found that pre-diagnostic plasma proteomics identified proteins and pathways with modest effect sizes and clear differences between future risk of colon and rectal cancer and motivate site-specific biomarker discovery that distinguishes colon from rectal cancer.

Xin-Yuan Zhang, Jonathan M. Downie, D. Drew et al. · 0 citations
Sep 2026

Abstract B096: Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer

It is suggested that productive immunotherapy responses in PDAC require not only tumor-reactive T cells, but also a stromal-vascular niche capable of supporting their recruitment, recirculation and persistence.

Sarah Kang, M. Parikh, Leontios Pappas et al. · 0 citations
Open access Oct 2026

A Phase II Study of Nivolumab and Ipilimumab with Radiation Therapy in Patients with Metastatic, Microsatellite Stable Colorectal Cancer.

The combination of immune-modulating, non-ablative doses of radiation therapy with ipilimumab and nivolumab has selective clinical activity in refractory MSS CRC, with responses concentrated primarily in patients without active liver metastases.

Leontios Pappas, J. Koenig, B. Yeap et al. · 0 citations
Open access Aug 2026

Addition of High-Dose Vitamin D3 to Standard Treatment in Patients with Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703)

High-dose vitamin D3 added to standard treatment improved progression-free survival (PFS) compared to standard-dose vitamin D3 in patients with metastatic colorectal cancer (mCRC) in a phase 2 randomized clinical trial.

K. Ng, F. Ou, T. Zemla et al. · 0 citations
Aug 2026

Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-Derived external control arms.

ARCAD-derived SCAs reliably reproduced control-arm OS and benchmark treatment-effect estimates from landmark RCTs in mCRC, and supports benchmarking, trial design, and exploratory analyses when conventional control arms are impractical.

M. Raeisi, T. André, Q. Shi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.